SLC5A2 and kidney disorder: Canagliflozin, traditionally known as an SGLT2 inhibitor targeting hyperglycemia, has been previously shown to preserve mitochondrial function in renal disease by restoring mitochondrial membrane potential, reducing mitochondrial ROS output, and normalizing activity across mitochondrial respiratory complexes [25].